Premium
Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis
Author(s) -
Manolio Teri A.,
Hutter Carolyn M.,
Avigan Mark,
Cibotti Ricardo,
Davis Robert L.,
Denny Joshua C.,
Grenade Lois La,
Wheatley Lisa M.,
Carrington Mary N.,
Chantratita Wasun,
Chung WenHung,
Dalton Andrea D.,
Hung ShuenIu,
Lee Ming Ta Michael,
Leeder J. Steven,
Lertora Juan J.L.,
Mahasirimongkol Surakameth,
McLeod Howard L.,
Mockenhaupt Maja,
Pacanowski Michael,
Phillips Elizabeth J.,
Pinheiro Simone,
Pirmohamed Munir,
Sung Cynthia,
Suwankesawong Wimon,
Trepanier Lauren,
Tumminia Santa J.,
Veenstra David,
Yuliwulandari Rika,
Shear Neil H.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.890
Subject(s) - toxic epidermal necrolysis , drug reaction , medicine , incidence (geometry) , drug , dermatology , genetic predisposition , complication , intensive care medicine , allele , surgery , pharmacology , genetics , disease , biology , physics , optics , gene
Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug‐induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.